ClinicalTrials.gg
Not yet recruitingNCT07747493PSMA-FTUpdated Aug 5, 2026

68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy

An interventional study of Gallium Ga 68 Gozetotide (68Ga-PSMA-11) and Intervention Description: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) combines molecular imaging with high-resolution anatomical MRI to evaluate intraprostatic lesions in Prostate Cancer (Adenocarcinoma) and Localized Prostate Cancer, sponsored by University Health Network, Toronto. Not yet recruiting at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms — 8 open to participants now, 11 under way, 3 of them phase 3. gallium 68 PSMA-11 · Prostatic Neoplasms.

Planned enrollment
42nd of 49
8 · median 50
Started
2026
with 2 others
No phase
4 of 49
2 open now
Primary completion
2027-07
later than 9 of 10 live
Registered
49th of 49
by date

Among the 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms, this one is the 42nd largest by planned enrollment, is one of 3 that started in 2026, is one of 4 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 49th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About gallium 68 PSMA-11

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Focal therapy is a minimally invasive treatment option for some men with localized prostate cancer. Unlike surgery or radiation, focal therapy treats only the area of the prostate containing clinically significant cancer, with the goal of preserving urinary and sexual function. Successful focal therapy depends on accurately identifying all areas of clinically significant prostate cancer before treatment. Currently, multiparametric magnetic resonance imaging (MRI) is the standard imaging method used to determine whether a patient is a suitable candidate for focal therapy. However, MRI may miss some clinically significant cancers, which can lead to incomplete treatment.

This pilot study will evaluate whether 68Ga-PSMA-11 positron emission tomography/magnetic resonance imaging (PET/MRI) can improve the selection of men with localized prostate cancer for focal therapy compared with MRI alone. The study will enroll men with intermediate-risk prostate cancer who are already planning to undergo radical prostatectomy as part of their standard care.

Participants will receive a single injection of 68Ga-PSMA-11 followed by a PET/MRI scan before surgery. The PET/MRI findings and MRI findings will be reviewed separately and compared with the prostate tissue examined after surgery, which serves as the reference standard for determining the true location and extent of cancer.

The main question this study is trying to answer is whether 68Ga-PSMA-11 PET/MRI is more accurate than MRI alone in identifying men who are appropriate candidates for focal therapy. The study will also evaluate whether PET/MRI detects more clinically significant prostate cancer lesions than MRI alone.

Researchers hypothesize that 68Ga-PSMA-11 PET/MRI will improve the detection of clinically significant prostate cancer and more accurately identify patients who are suitable candidates for focal therapy, potentially reducing the risk of untreated cancer remaining in the prostate after treatment. If successful, the results of this pilot study will support the development of a larger clinical trial and may help improve future treatment planning for men with localized prostate cancer.

Read the detailed description

Prostate cancer is one of the most commonly diagnosed cancers in men. For patients with localized, clinically significant disease, focal therapy has emerged as a minimally invasive treatment option that targets only the cancerous portion of the prostate while preserving surrounding healthy tissue. Compared with whole-gland treatments such as radical prostatectomy or radiation therapy, focal therapy has the potential to reduce treatment-related side effects, including urinary incontinence and erectile dysfunction, while maintaining cancer control in appropriately selected patients.

The success of focal therapy depends on accurately identifying all clinically significant prostate cancer within the prostate before treatment. Multiparametric magnetic resonance imaging (MRI) is currently the standard imaging modality used to evaluate patients being considered for focal therapy. Although MRI has substantially improved prostate cancer detection and localization, clinically significant tumors may remain undetected. Failure to identify all clinically significant disease may result in incomplete treatment, persistent cancer outside the treated area, or disease recurrence following focal therapy.

Prostate-specific membrane antigen (PSMA) is a protein that is highly expressed on the surface of most prostate cancer cells. Radiotracers that target PSMA, such as 68Ga-PSMA-11, allow prostate cancer lesions to be visualized using positron emission tomography (PET). When PET is combined with MRI in a hybrid PET/MRI scanner, molecular information from PET is integrated with the high-resolution anatomical detail provided by MRI. Previous studies have demonstrated that combining PSMA PET with MRI improves the detection of clinically significant prostate cancer compared with MRI alone, but the value of this approach for selecting patients for focal therapy has not been established.

This prospective pilot study will evaluate the diagnostic performance of 68Ga-PSMA-11 PET/MRI compared with MRI alone in men with localized intermediate-risk prostate cancer who have already elected to undergo radical prostatectomy as part of their standard clinical care. Because the prostate gland will subsequently be removed, detailed whole-mount histopathological examination of the surgical specimen can be used as the reference standard to determine the true location and extent of cancer throughout the prostate. This provides a unique opportunity to directly compare imaging findings with pathology.

Imaging findings from MRI alone and from integrated PET/MRI will be independently interpreted and compared with whole-mount histopathology to determine how each imaging strategy would influence patient selection for focal therapy. The study will assess whether additional lesions detected by PET/MRI would alter eligibility for focal therapy or require modification of the planned treatment strategy. The analysis will evaluate theoretical focal therapy approaches, including targeted, zonal, and hemi-gland ablation, based on the distribution of clinically significant disease identified on surgical pathology. Participants will not receive focal therapy as part of this study, and PET/MRI findings will not influence their clinical management.

The investigators hypothesize that 68Ga-PSMA-11 PET/MRI will improve identification of clinically significant prostate cancer compared with MRI alone and more accurately identify patients who are appropriate candidates for focal therapy. Improved patient selection has the potential to reduce treatment failures caused by undetected cancer outside the intended treatment area while preserving the quality-of-life benefits associated with focal therapy.

As a pilot feasibility study, the results will provide preliminary evidence to inform the design of a larger prospective clinical trial. If the findings demonstrate improved diagnostic performance, 68Ga-PSMA-11 PET/MRI may become an important imaging tool for patient selection in future focal therapy programs and clinical trials, ultimately supporting more individualized treatment planning for men with localized prostate cancer.

03

Conditions studied

  • Prostate Cancer (Adenocarcinoma)
  • Localized Prostate Cancer

Keywords

  • Prostate Cancer
  • Gallium Ga 68 Gozetotide
  • Positron Emission Tomography Magnetic Resonance Imaging
  • Multiparametric Magnetic Resonance Imaging
  • Focal Therapy
  • Localized Prostate Cancer
  • Intermediate-Risk Prostate Cancer
  • Radical Prostatectomy
  • Diagnostic Imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide written .
  • Age 18 years or older.
  • prostate cancer (csPCa) with clinical stage ≤ T2c and planned radical prostatectomy.
  • Serum prostate-specific antigen (PSA) ≤ 20 ng/mL.
  • Clinically significant prostate cancer within an MRI-visible lesion, defined as - International Society of Urological Pathology (ISUP) Grade Group 2 or 3 (Gleason score 3+4 or 4+3) in any core.

Exclusion criteria

Exclusion Criteria:

  • Inability to lie still for the PET/MRI examination.
  • Known or to gallium Ga 68 gozetotide (68Ga-PSMA-11) or to the MRI gadolinium contrast agent, including any component of the formulation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    68Ga-PSMA-11 PET/MRI Imaging

    Participants will receive a single intravenous administration of gallium Ga 68 gozetotide (68Ga-PSMA-11) (111-259 MBq) followed by integrated positron emission tomography/magnetic resonance imaging (PET/MRI) approximately 50-100 minutes after injection. PET/MRI findings will be compared with multiparametric MRI alone and whole-mount histopathology following planned radical prostatectomy to evaluate the diagnostic performance of 68Ga-PSMA-11 PET/MRI for selecting men with localized intermediate-risk prostate cancer for focal therapy. PET/MRI results will not influence clinical management, and all participants will proceed with standard-of-care radical prostatectomy.

    Drug: Gallium Ga 68 Gozetotide (68Ga-PSMA-11) · Diagnostic Test: Intervention Description: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) combines molecular imaging with high-resolution anatomical MRI to evaluate intraprostatic lesions

Interventions

  • DrugGallium 68 PSMA-11Studies of Gallium 68 PSMA-11Gallium 68 PSMA-11 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intervention Description: Gallium Ga 68 gozetotide (68Ga-PSMA-11) is a prostate-specific membrane antigen (PSMA)-targeted positron-emitting radiopharmaceutical used for PET imaging of prostate cancer. In this study, a single intravenous dose (111-259 MBq) will be administered before PET/MRI to evaluate its diagnostic performance for identifying clinically significant prostate cancer and improving selection of patients for focal therapy.

    Also known as: Diagnostic Test

  • Diagnostic testIntervention Description: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) combines molecular imaging with high-resolution anatomical MRI to evaluate intraprostatic lesions

    Gallium Ga 68 gozetotide (68Ga-PSMA-11) is a prostate-specific membrane antigen (PSMA)-targeted positron-emitting radiopharmaceutical approved for PET imaging of PSMA-expressing lesions in men with prostate cancer. In this study, it is administered as a single intravenous injection (111-259 MBq) before PET/MRI to evaluate its ability to improve detection of clinically significant intraprostatic disease and selection of patients for focal therapy compared with multiparametric MRI alone.

06

What researchers measure

Primary outcomes

  1. Specificity of 68Ga-PSMA-11 PET/MRI for Determining Eligibility for Focal Therapy

    To evaluate the specificity of 68Ga-PSMA-11 PET/MRI compared with multiparametric MRI alone for determining eligibility for focal therapy in men with localized intermediate-risk prostate cancer. Imaging findings will be compared with whole-mount histopathology following radical prostatectomy, which serves as the reference standard.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Detection Rate of 68Ga-PSMA-11 PET/MRI for Clinically Significant Prostate Cancer

    To evaluate the detection rate of 68Ga-PSMA-11 PET/MRI compared with multiparametric MRI alone for identifying clinically significant prostate cancer (International Society of Urological Pathology \[ISUP\] Grade Group ≥2) in men with localized intermediate-risk prostate cancer who are potential candidates for focal therapy. The outcome will be measured as the percentage of lesions correctly identified by each imaging modality using whole-mount histopathology following radical prostatectomy as the reference standard.

    Time frame: Through study completion, an average of 1 year

Other outcomes

  1. Primary Endpoint:

    Lesions identified by PSMA PET/MRI or MRI alone will be compared to histopathology after radical prostatectomy as reference standard (the hypothesis being that PET/MRI will exclude more patients from Focal Therapy who would be considered ineligible for FT by histopathology).

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jul 2027, 10 months later.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 10 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Aug 5, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07747493
Responsible party
Sponsor
First posted
Aug 5, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

Kateri Corr
Contact
kateri.corr@uhn.ca
1-416-500-5737
Adriano Basso Dias, MD, MSc, Radiologist
Contact
adriano.bassodias@uhn.ca
1-647-504-4609
Adriano Basso Dias, MD, MSc, Radiologist
principal investigator · University Health Network - Toronto General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium 68 PSMA-11

Start the discussion